Latest news with #NuvationBio
Business Insider
13-07-2025
- Business
- Business Insider
3 ‘Strong Buy' Russell 2000 Stocks with Triple-Digit Upside Potential
As the market continues to navigate economic uncertainty, investors are increasingly looking toward smaller companies with high growth potential. One area drawing attention is the Russell 2000 Index, which tracks 2,000 U.S. small-cap stocks. In this article, we spotlight three standout names: Syndax Pharmaceuticals (SNDX), Nuvation Bio (NUVB), and Aura Biosciences (AURA). Elevate Your Investing Strategy: Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week. Each of these companies is focused on developing cancer treatments and has earned Strong Buy ratings from analysts, thanks to their promising pipelines and significant upside potential. Let's dive into the details. Is Syndax a Good Stock to Buy? Syndax Pharmaceuticals is a commercial-stage biopharma company focused on developing and delivering innovative cancer treatments. Year-to-date, SNDX stock has declined by nearly 28%. Syndax stock price target of $31.25 suggests a 229% upside from current levels. Is Nuvation Bio a Good Buy? Nuvation Bio is a global drug company working to treat some of the toughest cancers by creating new and unique cancer medicines. Year-to-date, NUVB stock has declined by nearly 15%. This week, RBC Capital reiterated its Buy rating on NUVB stock, predicting an upside of over 160%. Overall, on TipRanks, NUVB has unanimous Buy recommendations from six analysts covering the stock. Meanwhile, Nuvation Bio's average price target of $7.4 suggests a potential upside of 227% from current levels. Is AURA a Good Stock to Buy? Aura Biosciences is a clinical-stage biotech company developing a new type of cancer treatment called virus-like drug conjugates (VDCs) to target different types of cancer. With promising early clinical data and a focus on hard-to-treat cancers like ocular melanoma, the company could offer strong long-term upside potential for investors. According to TipRanks, Aura Biosciences holds a Strong Buy consensus rating from Wall Street, with all six analysts recommending a Buy. Taken together, Aura Biosciences' stock forecast of $21.75 implies an upside of about 230%. Year-to-date, AURA stock has declined by almost 20%.
Business Insider
10-07-2025
- Business
- Business Insider
RBC Capital Reaffirms Their Buy Rating on Nuvation Bio (NUVB)
In a report released on July 7, Leonid Timashev from RBC Capital maintained a Buy rating on Nuvation Bio, with a price target of $6.00. The company's shares closed yesterday at $2.37. Don't Miss TipRanks' Half-Year Sale Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week. Timashev covers the Healthcare sector, focusing on stocks such as Legend Biotech, Biohaven Ltd., and Alkermes. According to TipRanks, Timashev has an average return of 1.5% and a 43.80% success rate on recommended stocks. Currently, the analyst consensus on Nuvation Bio is a Strong Buy with an average price target of $7.40, representing a 212.24% upside. In a report released on June 25, Citizens JMP also reiterated a Buy rating on the stock with a $6.00 price target. The company has a one-year high of $3.97 and a one-year low of $1.54. Currently, Nuvation Bio has an average volume of 5.58M. Based on the recent corporate insider activity of 13 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of NUVB in relation to earlier this year. Last month, Kerry Wentworth, the CHIEF REGULATORY OFFICER of NUVB bought 50,000.00 shares for a total of $89,740.00.
Yahoo
30-06-2025
- Business
- Yahoo
JMP Maintains 'Market Outperform' on Nuvation (NUVB) for IBTROZI Launch Plans
Nuvation Bio Inc. (NYSE:NUVB) is one of the 10 best healthcare penny stocks to buy according to analysts. JMP Securities analyst Silvan Tuerkcan maintained a 'Market Outperform' rating on Nuvation's stock on June 25. The analyst also kept the price target at $6.00 per share. A doctor reading the results of a Phase 2 clinical trial of treatments for cancer, infectious diseases and autoimmune and inflammatory diseases. Tuerkcan's decision follows Nuvation's detailed presentation of launch plans for its cancer treatment, IBTROZI (taletrectinib). The drug has received FDA approval for adults with locally advanced or metastatic ROS1-positive Non-Small Cell Lung Cancer (NSCLC). China's National Medical Products Administration (NMPA) also approved it earlier in January 2025 for the same indication. Nuvation plans to price the treatment at $29,844 per month. Tuerkcan's research note pointed out that IBTROZI maintains an approximately two-year lead over Nuvalent's (NASDAQ:NUVL) zidesamtinib in front-line treatment for ROS1-positive NSCLC. She also noted that the potent efficacy of both IBTROZI and zidesamtinib is expected to drive physician interest in new ROS1 TKI treatments and expand the ROS1 class of therapies. Nuvation Bio Inc. (NYSE:NUVB) is a clinical-stage biopharmaceutical company. It develops targeted cancer therapies for patients with tumors that are difficult to treat. Its lead product is IBTROZI. Other pipeline candidates include safusidenib (for brain tumors with IDH1 mutations), NUV-1511 (a drug-drug conjugate for solid tumors), and NUV-868 (a BET inhibitor targeting BRD4). While we acknowledge the potential of NUVB as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: Goldman Sachs Energy Stocks: 10 Stocks to Buy and 10 Best AI Stocks to Buy According to Billionaire David Tepper. Disclosure: None. Sign in to access your portfolio
Yahoo
26-06-2025
- Business
- Yahoo
RBC Capital Lowers PT on Nuvation Bio (NUVB) to $6 But Keeps a Buy Rating
Nuvation Bio Inc. (NYSE:NUVB) is one of the 13 Best Long-Term Penny Stocks to Buy According to Analysts. RBC Capital analyst Leonid Timashev maintained a Buy rating on Nuvation Bio Inc. (NYSE:NUVB) on June 17, lowering the price target to $6.00 from $10.00. The analyst told investors in a research note that the firm updated its model after the company's transformation into a commercial stage biotech and the recent approval of Ibtrozi to treat cancer. A close-up of researchers, carefully studying a biopharmaceutical compound in a laboratory. Timashev acknowledged that the firm sees some potential challenges for the launch of Ibtrozi, including near-term competitive headwinds and patient finding. However, RBC is optimistic that these headwinds will be outweighed by the drug's long treatment duration, favorable profile, and improving dx rates, supporting the positive rating for Nuvation Bio Inc. (NYSE:NUVB). The analyst also reasoned that the stock is steeply discounting the recently realized commercial opportunity. Nuvation Bio (NYSE:NUVB) is a biopharmaceutical company that develops therapeutic and differentiated candidates to tackle the gaps in oncology. It is advancing several clinical-stage candidates, including a bromodomain and extra-terminal (BET) inhibitor, a ROS1 inhibitor, a mutant isocitrate dehydrogenase 1 (mIDH1) inhibitor, and a drug-drug conjugate (DDC). While we acknowledge the potential of NUVB as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: The Best and Worst Dow Stocks for the Next 12 Months and 10 Unstoppable Stocks That Could Double Your Money. Disclosure: None.
Medscape
11-06-2025
- Business
- Medscape
Taletrectinib Approved for NSCLC
The FDA has approved taletrectinib (Ibtrozi, Nuvation Bio) for locally advanced or metastatic ROS1-positive non-small cell lung cancer (NSCLC) in first- and later-line settings, regardless of prior ROS1 tyrosine kinase inhibitor (TKI) exposure. Taletrectinib is considered a next-generation ROS1 TKI to distinguish it from two first-generation products already on the US market: crizotinib and entrectinib. A third ROS1 TKI approved in 2023, repotrectinib, is also a next-generation medicine. Like repotrectinib, FDA granted taletrectinib a breakthrough therapy designation. Compared with crizotinib and entrectinib, Nuvation Bio data suggests taletrectinib has greater brain penetration, lower incidence of neurologic adverse events, less likelihood of resistance, and other benefits, plus a possible safety and efficacy edge over next-generation rival repotrectinib. 'Taletrectinib will likely become the preferred treatment option for advanced ROS1+ NSCLC,' commented Thomas E. Stinchcombe, MD, an associate editor at the Journal of Clinical Oncology , in the 'Context' section of his journal's publication of a pooled analysis of Nuvation Bio's two approval studies, TRUST-I and TRUST-II, in April. Taletrectinib was originally developed in China and was approved there in Jan 2025 for the same indication granted by FDA. The company plans a US launch in mid-2025, they stated in a press release. About 2% of NSCLC patients have ROS1-positive disease, and about a third of them present with brain metastases. ROS1-positive patients have an oncogenic rearrangement in the ROS1 gene, which leads to an abnormal ROS1 fusion protein that drives cancer growth. ROS1 TKIs block the protein's activity. The drug's approval was based on results of TRUST-I and TRUST-II, phase 2, single-arm, open label studies in ROS1-positive NSCLC patients treated with oral taletrectinib 600 mg once daily until progression, unacceptable toxicity, death, or consent withdrawal. Of the 273 subjects in the pooled analysis, 93.8% had stage IV disease, 33.7% had brain metastases, and 27.1% had received chemotherapy. TRUST-I included Chinese subjects who were either new to TKIs or who had received crizotinib. TRUST-II included patients from North America, Europe, and Asia who were TKI-naive or who had been treated with crizotinib or entrectinib. The efficacy population included 157 patients (103 in TRUST-I; 54 in TRUST-II) who were naive to treatment with a ROS1 TKI and 113 patients (66 in TRUST-I; 47 in TRUST-II) who had received one prior ROS1 TKI. Patients may have received prior chemotherapy for advanced disease. For treatment-naive patients, the overall response rate (ORR) was 90% in TRUST-I and 85% in TRUST-II, with 72% and 63% of responders having a duration of response (DOR) of at least a year, respectively. For TKI-pretreated patients, ORR was 52% in TRUST-I and 62% in TRUST-II, with 74% and 83% of responders having a DOR of at least 6 months, respectively. Among 13 patients with a G2032R mutation, which triggers resistance to first generation ROS1 TKIs, eight (61.5%) had a response to taletrectinib. In a safety analysis with 352 patients, the most frequent treatment-emergent adverse events with taletrectinib were gastrointestinal problems (88%) and elevated aspartate aminotransferase (72%) and alanine aminotransferase (68%). Neurologic adverse events included dizziness (21%) and dysgeusia (15%). Overall, 33% of patients had grade 3 or higher treatment-related adverse events. Treatment-emergent adverse events led to discontinuation in 7% of patients. There were three treatment-related deaths due to abnormal hepatic function, liver failure, and pneumonia. Prescribing information for taletrectinib includes warnings and precautions for hepatotoxicity, interstitial lung disease/pneumonitis, QTc interval prolongation, hyperuricemia, myalgia with creatine phosphokinase elevation, skeletal fractures, and embryo-fetal toxicity. The recommended taletrectinib dose is 600 mg orally once daily on an empty stomach until disease progression or unacceptable toxicity. Taletrectinib pricing was not available, but fourteen 160 mg capsules of rival repotrectinib — the initial 2-week supply with daily dosages doubling afterwards — is $7,666.97, according to
